Company Overview of Allos Therapeutics, Inc.
Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of anti-cancer therapeutics. It focuses on the development and commercialization of FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is approved in the United States for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is also developing FOLOTYN in other hematologic malignancies. The company has a strategic collaboration agreement with Mundipharma International Corporation Limited (Mundipharma) to co-develop FOLOTYN. Allos Therapeutics, Inc. has commercialization rights for FOLOTYN in the United States and Canada; a...
11080 CirclePoint Road
Westminster, CO 80020
Founded in 1992
Key Executives for Allos Therapeutics, Inc.
Chief Financial Officer and Treasurer
Chief Medical Officer and Executive Vice President
Senior Vice President of Corporate Development
Compensation as of Fiscal Year 2013.
Allos Therapeutics, Inc. Key Developments
Allos Therapeutics, Inc. Enters into an Amended and Restated License, Development and Commercialization Agreement with Mundipharma International Limited
Jun 3 13
On May 29, 2013, Allos Therapeutics, Inc. entered into an Amended and Restated License, Development and Commercialization Agreement by and between the company and Mundipharma International Limited, which amended and restated a May 2011 agreement between the parties. The Amended License Agreement provides for a strategic collaboration between the parties related to the development of FOLOTYN. The company received a $50 million upfront payment upon execution of the May 2011 agreement. Under the Amended License Agreement, the company will receive $7 million as reimbursement of research and development costs incurred by the company through the date of the Amended License Agreement. Additionally, the company will be eligible to receive potential regulatory milestone payments of up to an aggregate of approximately $16 million based on approvals of FOLOTYN for the treatment of PTCL in a specified patient population in Japan, China, Latin America and Australia, respectively, commercial-progress based on initial sales in Japan and overall sales-dependent milestones of up to $107 million and tiered double digit royalties on net sales in the Mundipharma territories. Mundipharma is responsible for 40% of joint development costs incurred by the parties through May 31, 2013 related to certain FOLOTYN studies, with each party accountable for its future cost of conducting studies for which it is obligated and the allocation of responsibility for new studies to be agreed upon by the parties. Pursuant to the terms of the Amended License Agreement, the company will gain the commercialization rights to FOLOTYN in Europe and Turkey, with an option for Switzerland, while Mundipharma will retain exclusive rights to commercialize FOLOTYN in the Mundipharma territories, including Asia and Latin America. The Amended License Agreement will remain in effect, on a country-by-country basis, until the expiration of Mundipharma's obligation to pay royalties on net sales of the subject products in such country. Mundipharma may terminate the Agreement at its election upon 90 days' notice to the Company, or immediately in the event that the company's license agreement dated December 23, 2002, as amended, with SRI International, Sloan-Kettering Institute for Cancer Research and Southern Research Institute is terminated without Mundipharma's consent. The company may terminate the Agreement at its election immediately with respect to the territory of Japan only, in the event that Mundipharma does not achieve certain milestones in Japan. Additionally, either party may terminate the Agreement for an uncured material breach by the other party. Concurrently with the execution of the Amended License Agreement, the company and Mundipharma Medical Company entered into an Amended and Restated Supply Agreement, which amended and restated a May 2011 agreement between the parties. Pursuant to the terms of the Amended Supply Agreement, subject to certain exceptions, MMC agreed to purchase and the company agreed to supply MMC's clinical and commercial requirements of FOLOTYN. The term of the Amended Supply Agreement is concurrent with the term of the Amended License Agreement and may be terminated by either party for an uncured material breach by the other party or upon certain bankruptcy proceedings involving the other party.
Allos Therapeutics, Inc.(NasdaqGS:ALTH) dropped from NASDAQ Composite Index
Sep 5 12
Allos Therapeutics, Inc. will be removed from NASDAQ Composite Index
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos Therapeutics, Inc. and Spectrum Pharmaceuticals, Inc
May 1 12
Robbins Geller Rudman & Dowd LLP announced that a class action has been commenced in the United States District Court for the District of Colorado on behalf of all persons who held shares of the common stock of Allos Therapeutics, Inc. on April 5, 2012, against Allos, its board of directors and Spectrum Pharmaceuticals, Inc. for breaches of fiduciary duty in connection with the proposed acquisition of Allos by Spectrum and for violations of Section 14(e) of the Securities Exchange Act of 1934 in connection with the Solicitation/Recommendation Statement on Schedule 14D-9 filed with the SEC on April 13, 2012. On April 5, 2012, Allos and Spectrum announced a definitive merger agreement under which Allos would be acquired by Spectrum via tender offer. Under the terms of the Merger Agreement, upon successful completion of the Tender Offer, Allos stockholders will receive $1.82 per share in cash plus one Contingent Value Right, which would provide Allos stockholders with an additional payment of $0.11 per share in cash if certain European regulatory approval and commercialization milestones for FOLOTYN(R) are achieved. The complaint alleges that the defendants directly breached their fiduciary duties or aided and abetted breaches of fiduciary duties in connection with the Proposed Acquisition, which significantly undervalues Allos and is the result of an unfair sales process designed to ensure that only Spectrum has the opportunity to acquire Allos. In addition, the complaint alleges that the 14D-9 contains material omissions and/or misstatements in contravention of --14(e) of the 1934 Act and/or defendants' fiduciary duty of disclosure under state law, including material omissions and/or misstatements concerning the sales process leading up to the execution of the Merger Agreement, the Company's value, the analyses performed by the Company's financial advisor, J.P. Morgan Securities LLC, and the potential and/or actual conflicts of interest faced by J.P. Morgan. Without this material information, Allos shareholders are prevented from making a fully-informed decision as to the adequacy of the Tender Offer and whether to tender their shares.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|